Macrophage Activation Syndrome Following Initiation of Etanercept in a Child with Systemic Onset Juvenile Rheumatoid Arthritis

Overview

Journal J Rheumatol

Specialty Rheumatology

Date 2003 Feb 4

PMID 12563702

Citations 40

Authors

Athimalaipet V Ramanan

Rayfel Schneider

Affiliations

Soon will be listed here.

Abstract

Systemic onset juvenile rheumatoid arthritis (JRA) accounts for 10-15% of all JRA. Macrophage activation syndrome (MAS), which can also be considered as secondary hemophagocytic lymphohistiocytosis, is a potentially life-threatening complication of systemic onset JRA. We describe a child with systemic onset JRA who developed MAS after initiation of etanercept therapy.

Citing Articles

Implementation of the new DGRh S2e guideline on diagnostics and treatment of adult-onset Still's disease in Germany : Implications for clinical practice in rheumatology.

Friedrich R, Kernder A, Blank N, Ernst D, Henes J, Keysser G Z Rheumatol. 2024; 84(1):30-38.

PMID: 39668243 DOI: 10.1007/s00393-024-01607-7.

Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms.

Wu Y, Sun X, Kang K, Yang Y, Li H, Zhao A J Hematol Oncol. 2024; 17(1):106.

PMID: 39511607 PMC: 11542428. DOI: 10.1186/s13045-024-01621-x.

Kawasaki Disease-Associated Cytokine Storm Syndrome.

Tsoukas P, Yeung R Adv Exp Med Biol. 2024; 1448:365-383.

PMID: 39117827 DOI: 10.1007/978-3-031-59815-9_25.

Cytokine Storm Syndrome Associated with Systemic Juvenile Idiopathic Arthritis.

Vastert S, Canny S, Canna S, Schneider R, Mellins E Adv Exp Med Biol. 2024; 1448:323-353.

PMID: 39117825 DOI: 10.1007/978-3-031-59815-9_23.

Immunopathology of and potential therapeutics for secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome: a translational perspective.

Nguyen T, Kim Y, Jeong G, Jin M Exp Mol Med. 2024; 56(3):559-569.

PMID: 38448692 PMC: 10984945. DOI: 10.1038/s12276-024-01182-6.